AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, BNTX, ONC, TEVA, and SMMT
Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.
AstraZeneca vs.
Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
Novo Nordisk A/S currently has a consensus price target of $135.00, indicating a potential upside of 97.97%. AstraZeneca has a consensus price target of $88.00, indicating a potential upside of 26.29%. Given Novo Nordisk A/S's higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than AstraZeneca.
Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
In the previous week, Novo Nordisk A/S had 36 more articles in the media than AstraZeneca. MarketBeat recorded 65 mentions for Novo Nordisk A/S and 29 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.53 beat Novo Nordisk A/S's score of 0.55 indicating that AstraZeneca is being referred to more favorably in the news media.
11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote.
Novo Nordisk A/S has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.
Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. AstraZeneca pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Novo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks.
Get AstraZeneca News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
AstraZeneca Competitors List
Related Companies and Tools
This page (NASDAQ:AZN) was last updated on 5/22/2025 by MarketBeat.com Staff